No Data
Has Hangzhou Minsheng Healthcare Co., Ltd.'s (SZSE:301507) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Minsheng Health (301507.SZ): The products on sale are mainly vitamin and mineral supplement series products, mostly compound preparations.
On June 26th, Gelonghui: An investor asked Minsheng Health (301507.SZ) on the investor interactive platform, "How is the production and sales of the company in vitamin D?" The company responded that currently, the company's products for sale are mainly vitamin and mineral supplements, most of which are complex formulations, and do not involve the production and sales of active pharmaceutical ingredients. The company's vitamin D products mainly include 21st Century Calcium D3 Chewable Tablets, Vitamin D Vitamin K Vitamin E Soft Capsules, etc. Currently, the supply, production, and sales of this category of products' raw materials are normal, and fluctuations in the price of a single raw material have an impact on the overall cost of the product.
Minsheng Health (301507.SZ) has obtained a pharmaceutical registration certificate for aluminum magnesium carbonate mixed suspension.
On June 21st, Gelunhui reported that Minsheng Health (301507.SZ) received the aluminum magnesium carbonate mixed suspension drug registration certificate issued by the State Drug Administration, this pharmaceutical has obvious anti-acid effects and also has gastric mucosa protecting effects, as well as some adsorption effects on bile, the effect is rapid, mild and long-lasting. Indications: Chronic gastritis; Symptoms of discomfort related to gastric acid, such as stomach pain, heartburn, acid belching, bloating, etc.
Minsheng Health (301507.SZ): The new retail health products division is currently mainly responsible for online sales of health products.
On June 21st, Gelon Hui stated that when conducting research for specific objects, Minsheng Health (301507.SZ) indicated that the OTC division of the company is divided into the OTC Business Division and the OTC Retail Division. The OTC Business Division is responsible for connecting with dealers while the OTC Retail Division mainly focuses on traditional chain pharmacies. The Business Development Division is responsible for connecting with other standalone drugstores, third-party terminals, and mainly new product developments. The New Retail Healthcare Division is currently mainly responsible for online sales of healthcare products.
Minsheng Health (301507.SZ): currently has no direct sales to overseas markets.
On June 19th, Gelunhui reported that Minsheng Health (301507.SZ) recently stated during an investor reception that the company currently does not have direct sales in overseas markets, but will actively evaluate the possibility of exporting company products and importing high-quality foreign products in the future.
Minsheng Health (SZ301507): Probiotics are the market that the company is focusing on, and work such as strain screening is currently underway.
On June 19th, Gelunhui reported that Minsheng Health (301507.SZ) recently stated during an institutional investor survey that the company's probiotics series is produced and sold by its wholly-owned subsidiary Zhejiang Minsheng Health Technology Co., Ltd. In order to reduce and avoid competition within the industry, the company acquired a health technology company under the same control. Currently, the company is focusing on basic work such as product and business model adjustments. Probiotics are a market that the company is closely following, and the company is conducting strain screening, strain bank construction, and actively applying for new patents to prepare for the launch of new probiotic products. The company has always valued R&D work, and invests in R&D every year.
No Data
